Cupps Capital Management’s Acceleron Pharma XLRN Stock Holding History

Cupps Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$966K	Sell	26,699 -16,548	-38%	-$548K	0.42%	94
2016 Q2	$1.47M	Sell	43,247 -163	-0.4%	-$5.3K	0.38%	100
2016 Q1	$1.15M	Buy	43,410 +41,635	+2,346%	+$1.21M	0.22%	120
2015 Q4	$86K	Buy	+1,775	New	+$63.9K	0.01%	139

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVMCI

Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Cupps Capital Management's XLRN Position: Q3 2016 in Review

Cupps Capital Management reduced its Acceleron Pharma (XLRN) stake by 38% in Q3 2016, selling an estimated $548K and leaving 26,699 shares worth $966K. The position accounts for 0.42% of the portfolio, ranked #94.

Cupps Capital Management first reported a position in XLRN in Q4 2015 and has held it in 4 quarters since. The position peaked at $1.47M in Q2 2016. 139 funds tracked by Wall St. Rank hold XLRN as of Q3 2016.

Cupps Capital Management held 26,699 shares of Acceleron Pharma worth $966K as of Q3 2016.
Cupps Capital Management sold 16,548 Acceleron Pharma shares in Q3 2016, an estimated $548K.
Acceleron Pharma made up 0.42% of Cupps Capital Management's portfolio in Q3 2016, its #94 holding.
Cupps Capital Management first reported a position in Acceleron Pharma in Q4 2015 and has held it in 4 quarters since.
Cupps Capital Management's Acceleron Pharma position peaked at $1.47M in Q2 2016.
139 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2016.

Based on Cupps Capital Management's 13F filing for Q3 2016, filed 11 Oct 2016.